Defining targets for the treatment of delayed cerebral vasospasm after SAH
Project Number7R01NS074997-05
Former Number5R01NS074997-04
Contact PI/Project LeaderPROVENCIO, JOSE JAVIER
Awardee OrganizationUNIVERSITY OF VIRGINIA
Description
Abstract Text
DESCRIPTION (provided by applicant): The goal of this research proposal is to investigate the role of neutrophils in the development of delayed neurologic deterioration (DND) after subarachnoid hemorrhage (SAH). The research strategy utilizes a novel and unique mouse model of SAH and a newly described inducible CXCR2 knockout mouse. The model of SAH was developed during funding from an NIH scientist development grant (K08) mechanism. The overall hypothesis is that the development of DND is mediated by recruited neutrophils entering the CNS after SAH and from neutrophil effector mechanisms once in the CNS. Performance of this research will advance current knowledge in three ways: 1) It will characterize the specific neuronal changes developed during SAH and determine the role of neutrophils in neuronal injury. It will clarify the role of the recruited neutrophil population in the development of DND tat is critical to understanding whether prevention of neutrophil entry into the CNS after SAH will be a target for treatment, and SAH. And finally it will help answer the question of whether medications administered after SAH that block neutrophils will be useful to treat DND. The Specific Aims are: 1: We will define the role of neutrophils in neuronal damage after SAH.. 2: We will reconstitute migration and effector function-competent neutrophils in CXCR2 deficient mice at multiple time points AFTER SAH to define the role of the recruited neutrophils in DND. 3: We will deplete neutrophils at time points after the SAH to define the critical times for neutrophil damage in SAH. This knowledge will identify targets for treatment in SAH and DND.
Public Health Relevance Statement
Subarachnoid hemorrhage (SAH) due to bleeding from a brain aneurysm can lead to permanent disability often caused by a syndrome called delayed neurologic deterioration (DND). DND occurs 4 to 14 days after a subarachnoid hemorrhage and can lead to stroke and brain damage. Inflammation from neutrophils has been shown to be a contributor to the development of DND. Determining the mechanism by which neutrophils cause damage to neurons is critical to devising potential treatments. Additionally, neutrophils are usually not present in the brain. After SAH, some neutrophils get in to the brain through the burst aneurysm. Others are called into the brain later. It is still unclear whether the initial grop of neutrophils or the ones called into the brain are more important in the development of DND. This is important because it is unlikely that we can prevent neutrophils that enter the brain during the rupture of the aneurysm. Therefore, treatments based on this strategy depend on our understanding of this biology.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
065391526
UEI
JJG6HU8PA4S5
Project Start Date
01-November-2015
Project End Date
30-June-2017
Budget Start Date
01-November-2015
Budget End Date
30-June-2016
Project Funding Information for 2015
Total Funding
$321,985
Direct Costs
$207,458
Indirect Costs
$114,527
Year
Funding IC
FY Total Cost by IC
2015
National Institute of Neurological Disorders and Stroke
$321,985
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R01NS074997-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01NS074997-05
Patents
No Patents information available for 7R01NS074997-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01NS074997-05
Clinical Studies
No Clinical Studies information available for 7R01NS074997-05
News and More
Related News Releases
No news release information available for 7R01NS074997-05
History
No Historical information available for 7R01NS074997-05
Similar Projects
No Similar Projects information available for 7R01NS074997-05